Cargando…

Electrophoretic drug delivery for seizure control

The persistence of intractable neurological disorders necessitates novel therapeutic solutions. We demonstrate the utility of direct in situ electrophoretic drug delivery to treat neurological disorders. We present a neural probe incorporating a microfluidic ion pump (μFIP) for on-demand drug delive...

Descripción completa

Detalles Bibliográficos
Autores principales: Proctor, Christopher M., Slézia, Andrea, Kaszas, Attila, Ghestem, Antoine, del Agua, Isabel, Pappa, Anna-Maria, Bernard, Christophe, Williamson, Adam, Malliaras, George G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114990/
https://www.ncbi.nlm.nih.gov/pubmed/30167463
http://dx.doi.org/10.1126/sciadv.aau1291
_version_ 1783351302188695552
author Proctor, Christopher M.
Slézia, Andrea
Kaszas, Attila
Ghestem, Antoine
del Agua, Isabel
Pappa, Anna-Maria
Bernard, Christophe
Williamson, Adam
Malliaras, George G.
author_facet Proctor, Christopher M.
Slézia, Andrea
Kaszas, Attila
Ghestem, Antoine
del Agua, Isabel
Pappa, Anna-Maria
Bernard, Christophe
Williamson, Adam
Malliaras, George G.
author_sort Proctor, Christopher M.
collection PubMed
description The persistence of intractable neurological disorders necessitates novel therapeutic solutions. We demonstrate the utility of direct in situ electrophoretic drug delivery to treat neurological disorders. We present a neural probe incorporating a microfluidic ion pump (μFIP) for on-demand drug delivery and electrodes for recording local neural activity. The μFIP works by electrophoretically pumping ions across an ion exchange membrane and thereby delivers only the drug of interest and not the solvent. This “dry” delivery enables precise drug release into the brain region with negligible local pressure increase. The therapeutic potential of the μFIP probe is tested in a rodent model of epilepsy. The μFIP probe can detect pathological activity and then intervene to stop seizures by delivering inhibitory neurotransmitters directly to the seizure source. We anticipate that further tailored engineering of the μFIP platform will enable additional applications in neural interfacing and the treatment of neurological disorders.
format Online
Article
Text
id pubmed-6114990
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher American Association for the Advancement of Science
record_format MEDLINE/PubMed
spelling pubmed-61149902018-08-30 Electrophoretic drug delivery for seizure control Proctor, Christopher M. Slézia, Andrea Kaszas, Attila Ghestem, Antoine del Agua, Isabel Pappa, Anna-Maria Bernard, Christophe Williamson, Adam Malliaras, George G. Sci Adv Research Articles The persistence of intractable neurological disorders necessitates novel therapeutic solutions. We demonstrate the utility of direct in situ electrophoretic drug delivery to treat neurological disorders. We present a neural probe incorporating a microfluidic ion pump (μFIP) for on-demand drug delivery and electrodes for recording local neural activity. The μFIP works by electrophoretically pumping ions across an ion exchange membrane and thereby delivers only the drug of interest and not the solvent. This “dry” delivery enables precise drug release into the brain region with negligible local pressure increase. The therapeutic potential of the μFIP probe is tested in a rodent model of epilepsy. The μFIP probe can detect pathological activity and then intervene to stop seizures by delivering inhibitory neurotransmitters directly to the seizure source. We anticipate that further tailored engineering of the μFIP platform will enable additional applications in neural interfacing and the treatment of neurological disorders. American Association for the Advancement of Science 2018-08-29 /pmc/articles/PMC6114990/ /pubmed/30167463 http://dx.doi.org/10.1126/sciadv.aau1291 Text en Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). http://creativecommons.org/licenses/by-nc/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license (http://creativecommons.org/licenses/by-nc/4.0/) , which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.
spellingShingle Research Articles
Proctor, Christopher M.
Slézia, Andrea
Kaszas, Attila
Ghestem, Antoine
del Agua, Isabel
Pappa, Anna-Maria
Bernard, Christophe
Williamson, Adam
Malliaras, George G.
Electrophoretic drug delivery for seizure control
title Electrophoretic drug delivery for seizure control
title_full Electrophoretic drug delivery for seizure control
title_fullStr Electrophoretic drug delivery for seizure control
title_full_unstemmed Electrophoretic drug delivery for seizure control
title_short Electrophoretic drug delivery for seizure control
title_sort electrophoretic drug delivery for seizure control
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114990/
https://www.ncbi.nlm.nih.gov/pubmed/30167463
http://dx.doi.org/10.1126/sciadv.aau1291
work_keys_str_mv AT proctorchristopherm electrophoreticdrugdeliveryforseizurecontrol
AT sleziaandrea electrophoreticdrugdeliveryforseizurecontrol
AT kaszasattila electrophoreticdrugdeliveryforseizurecontrol
AT ghestemantoine electrophoreticdrugdeliveryforseizurecontrol
AT delaguaisabel electrophoreticdrugdeliveryforseizurecontrol
AT pappaannamaria electrophoreticdrugdeliveryforseizurecontrol
AT bernardchristophe electrophoreticdrugdeliveryforseizurecontrol
AT williamsonadam electrophoreticdrugdeliveryforseizurecontrol
AT malliarasgeorgeg electrophoreticdrugdeliveryforseizurecontrol